文献速递神经肿瘤

上皮生长因子受体表达影响5-ALA诱导的胶质母细胞瘤荧光

Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
PubMed 文献 · J Neurooncol · 2017-05-12

该体外研究在多种胶质母细胞瘤细胞系中分析5-ALA诱导荧光与EGFR及EGFRvIII表达的关系,发现EGF通过浓度依赖性促进HO-1转录表达降低细胞荧光,SnPP或siHO-1可恢复荧光,吉非替尼仅恢复U87MG细胞荧光,作者提出EGFRvIII共表达而非EGFR定量表达影响HO-1活性及细胞荧光。

要点

  • U87MG与LN229EGFR细胞的5-ALA诱导荧光与BS153细胞存在显著差异
  • EGF浓度依赖性促进HO-1转录表达并显著降低U87MG和LN229EGFR细胞荧光
  • SnPP或siHO-1恢复所有细胞系荧光,不依赖EGFR定量与定性表达

核心结论

  • 在胶质母细胞瘤细胞系中,5-ALA诱导荧光存在变异,并受EGF诱导的HO-1下游激活影响
  • HO-1蛋白表达被确定为胶质母细胞瘤细胞中5-ALA诱导荧光的负调控因子
  • 作者进一步提出,EGFRvIII共表达而非EGFR定量表达影响HO-1活性及细胞荧光

研究设计与样本

  • 体外研究,在多种胶质母细胞瘤细胞系中分析5-ALA诱导荧光与EGFR及EGFRvIII表达的关系
  • 分析EGF激活EGFR及其下游对HO-1的影响,并测试SnPP药理抑制、siRNA基因敲低HO-1及吉非替尼抑制EGFR的效果

主要发现

  • U87MG(低EGFR表达)和LN229EGFR细胞(EGFR过表达)与BS153细胞(EGFR过表达/EGFRvIII+)相比,5-ALA诱导荧光存在显著差异
  • EGF处理U87MG和LN229EGFR细胞以浓度依赖性方式促进HO-1转录和表达,显著降低细胞荧光
  • EGFR特异性siRNA处理可逆转该效应,在U87MG中降低约80%的蛋白表达
  • SnPP抑制HO-1活性或siHO-1降低HO-1蛋白水平可恢复所有细胞系的荧光,不依赖EGFR定量和定性表达
  • 吉非替尼处理可恢复U87MG细胞EGF刺激后的荧光,但不能恢复过表达EGFR/EGFRvIII的BS153细胞的荧光

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The extent of 5-aminolevulinic acid (5-ALA) guided tumor resection has a determining impact in high-grade glioma and glioblastoma surgery. Yet the intensity of the 5-ALA induced fluorescence may vary within the tumor. We aimed to correlate 5-ALA induced fluorescence with the expression of epithelial growth factor receptor (EGFR) and its constitutively active version EGFRvIII in different glioblastoma (GBM) cell lines. To elucidate the role of EGFR in the metabolism of 5-ALA in GBM cell lines with variable EGFR expression status, we analyzed the activation of EGFR by its primary ligand EGF, and its downstream effect on Heme oxygenase-1 (HO-1), a key enzyme regulating the metabolism of Protoporphyrin IX (PpIX), the fluorescent metabolite of 5-ALA. Effects of direct pharmacological inhibition by Tin(IV)-Protoporphyrin (SnPP) or gene knockdown by small interfering RNA (siRNA) on HO-1 enzyme were analyzed in respect to 5-ALA induced fluorescence. Furthermore, inhibition of EGFR by Gefitinib was tested. A significant difference in 5-ALA induced fluorescence was obtained in U87MG (low EGFR expression) and LN229EGFR cells (EGFR overexpression) compared to BS153 (EGFR overexpression/EGFRvIII+). Treatment of U87MG and LN229EGFR cells with EGF significantly reduced cellular fluorescence, by promoting HO-1 transcription and expression in a concentration-dependent manner. This effect could be reversed by EGFR-specific siRNA treatment, which reduced protein expression of about 80% in U87MG. Remarkably, inhibition of HO-1 activity by SnPP or reduction of HO-1 protein levels by siHO-1 treatment restored fluorescence in all cell lines, independently of EGFR quantitative and qualitative expression. Gefitinib treatment was able to restore fluorescence after EGF stimulation in U87MG cells but not in BS153 cells, overexpressing EGFR/EGFRvIII. In GBM cell lines, 5-ALA induced fluorescence is variable and influenced by EGF-induced downstream activation of HO-1. HO-1 protein expression was identified as a negative regulator of 5-ALA induced fluorescence in GBM cells. We further propose that co-expression of EGFRvIII but not quantitative EGFR expression influence HO-1 activity and therefore cellular fluorescence.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Fontana AO, Piffaretti D, Marchi F, et al. Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence. J Neurooncol. 2017. PMID: 28500562. doi:10.1007/s11060-017-2474-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。